Swiss medtech startup RetinAI Medical has announced the successful closing of a Series B funding round to advance its AI-driven platform for diabetic retinopathy screening. The investment, led by Swisscanto Invest and VI Partners, aims to accelerate the deployment of RetinAI's solutions across European ophthalmology clinics.

Diabetic retinopathy is a leading cause of vision impairment among adults, and early detection is crucial for effective intervention. RetinAI's software leverages artificial intelligence to analyze retinal images, supporting clinicians in identifying disease progression and optimizing patient management.

The new funding will support further clinical validation, regulatory expansion, and integration with electronic health records. For more information, visit RetinAI Medical's official announcement.